Projekt

LEADERS FREE III

Abgeschlossen · 2017 bis 2021

Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Abgeschlossen
Start
2017
Ende
2021
Finanzierungsart
Industrie
Studiendesign
Prospective, multi-center, open-label single-arm study designed to enroll 370 patients at up to 20 Centers. All patients will be followed up for 2 years.
Schlagwörter (Tags)
CAD, Stent
Kurzbeschreibung/Zielsetzung

A study evaluating the safety and efficacy of the BioFreedomTM Biolimus A9TM coated Cobalt Chromium coronary stent system in patients at high risk of bleeding.
The objective of this study is to evaluate if the BioFreedomTM CoCr Drug Coated stent has a similar clinical safety and efficacy characteristics to the BioFreedomTM SS Drug Coated stent.
Primary Safety Endpoint: MACE, defined as a composite of cardiac death, MI and definite/probable ST at one year.
Primary Efficacy Endpoint: Clinically driven target lesion revascularization (TLR) at one year.